JP6034861B2 - ジュウテリウム富化4−ヒドロキシ−5−メトキシ−n,1−ジメチル−2−オキソ−n−[(4−トリフルオロ−メチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド - Google Patents
ジュウテリウム富化4−ヒドロキシ−5−メトキシ−n,1−ジメチル−2−オキソ−n−[(4−トリフルオロ−メチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド Download PDFInfo
- Publication number
- JP6034861B2 JP6034861B2 JP2014516322A JP2014516322A JP6034861B2 JP 6034861 B2 JP6034861 B2 JP 6034861B2 JP 2014516322 A JP2014516322 A JP 2014516322A JP 2014516322 A JP2014516322 A JP 2014516322A JP 6034861 B2 JP6034861 B2 JP 6034861B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- deuterium
- abr
- formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910052805 deuterium Inorganic materials 0.000 title claims description 67
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 title claims description 64
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 title claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- 230000003211 malignant effect Effects 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000003463 hyperproliferative effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000036737 immune function Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 230000001668 ameliorated effect Effects 0.000 claims description 5
- 150000001767 cationic compounds Chemical class 0.000 claims description 5
- 229910001411 inorganic cation Inorganic materials 0.000 claims description 5
- UTUYWZJPVLDHJJ-UHFFFAOYSA-N n-methyl-4-(trifluoromethyl)aniline Chemical compound CNC1=CC=C(C(F)(F)F)C=C1 UTUYWZJPVLDHJJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000002892 organic cations Chemical class 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002887 deanol Drugs 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- OQZQXOFJGSSYNX-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxamide Chemical compound C1=CC=C2NCC(C(=O)N)=CC2=C1 OQZQXOFJGSSYNX-UHFFFAOYSA-N 0.000 claims 1
- NAHJLLJQGJMMRD-UHFFFAOYSA-N 4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound CN1C(=O)C(C(O)=O)=C(O)C2=C1C=CC=C2OC NAHJLLJQGJMMRD-UHFFFAOYSA-N 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 239000002207 metabolite Substances 0.000 description 20
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 17
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 101150055214 cyp1a1 gene Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229950001899 tasquinimod Drugs 0.000 description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 6
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020005029 5' Flanking Region Proteins 0.000 description 3
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 150000001975 deuterium Chemical group 0.000 description 3
- 125000004431 deuterium atom Chemical group 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000001589 microsome Anatomy 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- -1 quinoline-O-methyl Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 2
- 229960004577 laquinimod Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108010006109 methoxyresorufin-O-demethylase Proteins 0.000 description 2
- KXWAXDAVHXZBSL-UHFFFAOYSA-N methyl 4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1OC KXWAXDAVHXZBSL-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- UTUYWZJPVLDHJJ-MICDWDOJSA-N n-(deuteriomethyl)-4-(trifluoromethyl)aniline Chemical compound [2H]CNC1=CC=C(C(F)(F)F)C=C1 UTUYWZJPVLDHJJ-MICDWDOJSA-N 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- KNYYMGDYROYBRE-UHFFFAOYSA-N 7-methoxyphenoxazin-3-one Chemical compound C1=CC(=O)C=C2OC3=CC(OC)=CC=C3N=C21 KNYYMGDYROYBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- INQOMBQAUSQDDS-MICDWDOJSA-N deuterio(iodo)methane Chemical compound [2H]CI INQOMBQAUSQDDS-MICDWDOJSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000011099 endometrial disease Diseases 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000052268 human CYP1A1 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- BOFQMTZHRRRJED-MICDWDOJSA-N n-(deuteriomethyl)-2,2,2-trifluoro-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C(=O)N(C[2H])C1=CC=C(C(F)(F)F)C=C1 BOFQMTZHRRRJED-MICDWDOJSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Description
R2、R3及びR4は、H及びDから独立に選ばれ;そして
CR2R3R4は、少なくとも70%の総ジュウテリウム富化率を有する]に従う。
R2、R3及びR4は、H及びDから独立に選ばれ;そして
CR2R3R4は、少なくとも70%の総ジュウテリウム富化率を有する]を有する。
ABR−215050のCYP1A誘導能力のインビトロアッセイ
CYP1A1の転写機序は、インデューサーのAh受容体への結合と、それに続くリガンド−Ah−受容体複合体の核への転位を含む。そこでCYP1A1遺伝子の5’−フランキング領域の特定エンハンサー配列に結合する。これらの配列は、異物応答配列(XRE)と呼ばれる。
ABR−215050で使用したのと同じアッセイを使用した。使用されたABR−215691の濃度と、得られた結果(ルシフェラーゼ発現の誘導倍率として表されている)を表4及び図1に示す。
ジュウテリウム化(ジュウテリウム富化とも呼ぶ)ABR−215050を合成した。ここではアミド−Nメチル部分をトリジュウテリウム化した(ABR−215050−dx)。このジュウテリウム化化合物を非ジュウテリウム化ABR−215050で1:1のモル比に希釈した。1:1等モル混合物をインビボ実験でラットに投与した。キノリン骨格を追加的に13−炭素標識したため、形成されたアミド−N脱メチル代謝産物は、HPLC−MS(質量分析付き高速液体クロマトグラフィー検出)によって選択的に測定することができる。表5に、4匹の異なるラットで測定されたABR−215050−dx及びABR−215050の血漿中濃度(nM)と、これら二つの化合物の比率を示す。
ABR−215050及びABR−215050−dxの反復投与後のCYP1A1及びCYP1A2のインビボ誘導をラットで研究した。
試験製剤B及びC、及びブランク製剤Aを以下のように製造した。製剤Bの場合、ABR−215050をNaOHと無菌水中に0.5mg/mLの濃度で溶解した。溶液のpHをpH7.4〜8.5に調整した。製剤Cは、ABR−215050−dxを用いて同様に製造された。製剤Aは水しか含有していないブランクであった。製剤は冷蔵庫に最大1週間保管後、使用した。表7に製剤データをまとめた。
研究所に到着時、試験動物は9週齢のSprague−Dawley雄ラットで、体重は250gであった。これらを3群に分け、試験前に少なくとも7日間馴化させた。全馴化及び試験期間中、動物には水と餌(Labfor R70、form Kimstad、スウェーデン)を自由に与え、12時間ずつの明暗サイクル下、20±2℃の温度及び50±15%の相対湿度で飼育した。
いずれの試験製剤も投与前に、各動物の体重を測定し、動物に投与される個別用量を動物の体重を基に決定した。投与は4日間、経口により実施された。表8参照。
最終用量の投与の少し前に、血液サンプルをラット番号5の伏在静脈から採取した。投与期間終了時(第4日)、投与化合物及びアミド−N脱メチル化代謝産物の血漿中濃度を分析するために、血液サンプルをヘパリン化管に採取した。サンプルは、表9に示されたスケジュールに従って、伏在静脈から(約250μLの血液)及び大静脈から(可能な最大容量)抜き取った。
最終用量の投与24時間後、動物を体重測定し、各動物から最終血液サンプルを薬物動態分析のために抜き取った。次に動物を安楽死させ、それぞれから肝臓を取り出し、秤量し、直ちに破砕ドライアイス中で凍結した。次に肝臓をミクロソーム調製まで−70℃で保管した。
ミクロソームは、方法M−0287“動物組織からの細胞内画分の調製”に従って調製した後、分析まで−70℃に維持した。
ミクロソーム画分の総タンパク質濃度を方法M−0289“Hartreeによるタンパク質の決定”に従って決定した。
CYP1A1/2酵素活性は、方法M−0272Aに従って、ミクロソーム画分をCYP基質としてメトキシレゾルフィン(MROD)及びエトキシレゾルフィン(EROD)とインキュベーションすることによって測定した。ERODはCYP1A1に対して高い特異性を示すが、MRODはCYP1A2に対して高い特異性を示す。
ジュウテリウム化ABR−215050の抗腫瘍効果をマウスで研究した。
去勢抵抗性サブラインLNCaP−19を予めLNCaP細胞から確立した(12)。細胞は前述の通りに維持された(13)。LNCaP−19細胞は、実験に使用されたとき、10〜23継代の間であった。継代1は、我々の研究室における第一継代と定義される。細胞は試験の結果、マイコプラズマを含まないことが分かった。
雄の無胸腺ヌードBALB/cマウス(8週齢)をTaconic社(Lille Skensved、デンマーク)から購入した。皮下移植のために、200μlのマトリゲル(BD Bioscience社、マサチューセッツ州ベッドフォード)中に懸濁させた100万個の腫瘍細胞をマウスの脇腹に植え込んだ。腫瘍サイズは、実験期間を通して週1回カリパスで測定した。腫瘍獲得は非処置対照群(n=12)で75%であった。腫瘍増殖実験中、ABR−215050−dx(10mg/kg/日)を7日目から飲料水を通じて投与した。適切な用量が著しい変動なしに投与されていることを確かめるために、全実験期間を通じて各動物ケージの水消費量をモニターした。タスキニモド(tasquinimod)の血漿中半減期は3.4時間であること、飲料水による1〜10mg/kg/日の投与は、定常状態血漿中濃度(0.4〜1μM)をもたらすことがこれまでに示されている(14)。動物は、対照群の平均腫瘍サイズが900±100mm3の容積に達したら、又は個々の動物の腫瘍容積が1200mm3に達したら犠死させた。結果を図7に示す。
4−ヒドロキシ−5−メトキシ−1−メチル−2−オキソ−1,2−ジヒドロ−キノリン−3−カルボン酸メチルエステル(1.0g、3.79mmol)、N−ジュウテリオメチル−p−トリフルオロメチルアニリン(1.0g)、トリブチルアミン(100マイクロリットル)及びn−オクタン(70mL)を加熱還流し、揮発性物質を6時間にわたってゆっくり蒸留除去した。反応終了時に約60mLの溶媒が蒸留除去され、混合物は室温に冷却された。n−ヘプタン(25mL)とトルエン(6mL)の混合物を加え、結晶性懸濁液を20分間撹拌し、結晶をろ過により回収し、n−ヘプタンで洗浄し、乾燥させて粗標記化合物を得た(1.52g)。これを、メタノール(11.2mL)、水(6.8mL)及び水酸化ナトリウム(5M、0.83mL、4.15mmol)の混合物中に溶解した。塩酸(5M)を加えてpHをおよそ8〜9に調整し、混合物をろ過して不溶性物質があれば除去した。ろ液に5MのHClをpHがおよそ2になるまで加えた。懸濁液を1時間撹拌し、結晶をろ過により回収し、33%MeOH水溶液、次いで水で洗浄し、最後に真空下で乾燥させて標記化合物を得た(1.25g、80%)。H-nmr (CDCl3); 9.95 (s, 1H), 7.50 (m, 5H), 6.93 (d, 1H), 6.70 (d, 1H), 4.04 (s, 3H), 3.55 (s, 3H)。C20H14N2D3O4F3の分析計算値:C 58.68、H 4.22、N 6.84。実測値:C 58.8、H 4.25、N 6.94。大気圧エレクトロスプレーイオン化(ESI)質量分析:(M+H) 計算値410、実測値410。図3参照。
(1) PCT application WO 01/30758 A1.
(2) Isaacs J, Pili R, Qian D, Dalrymple S, Garrison J, Kyprianou N, Bjork A, Olsson A, Leandersson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006 Dec 1;66(16):1768-78.
(3) Dalrymple S, Becker E, Isaacs J. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhanced the anti-prostate cancer efficacy of androgen ablation and Taxotere without affecting serum PSA directly in human xenograft models. Prostate. 2007 67:790-797
(4) Clinical Phase-II study “EudraCT No: 2007-003470-26”.
(5) Trentham D. E. 1982. Collagen arthritis as a relevant model for rheumatoid arthritis. Evidence pro and con. Arthr. Rheum. 25, 911-916
(6) International patent application No.WO00/03991
(7) US patent application No. 2010/0055072 A1
(8) London, 13 December 2007 Doc.Ref.EMEA/CHMP/EWP/490784/2007
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/11/WC500015483.pdf
(9) Postlind, H., Vu, T.P., Tukey, R.H., and Quattrochi, L.C. (1993). Response of Human CYP1-Luciferase Plasmids to 2,3,7,8-Tetrachlorodibenzo-p-dioxin and Polycyclic Aromatic Hydrocarbons. Toxicol. Appl. Pharmco. 118, 255-262
(10) Edward Kerns and Li Di. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press, 2008, ISBN 978-0-12-369520-8, p.139
(11) The American Autoimmune Related Diseases Association, Inc. (AARDA) 22100 Gratiot Ave. East Detroit, MI 48021, USA
http://www.aarda.org/research_display.php?ID=47
(12) Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate. 2005;62:364-73.
(13) Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate. 2006; 66:1631-40.
(14) Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Bjork A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006; 66:1768-78.
(15) Jonsson et al, J. Med. Chem., 2004, 47, 2075-2088
Claims (15)
- アミド−Nメチル基における少なくとも70%のジュウテリウム富化率を有するジュウテリウム富化4−ヒドロキシ−5−メトキシ−N,1−ジメチル−2−オキソ−N−[(4−トリフルオロメチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド、又はその製薬学的に許容可能な有機又は無機カチオンとの塩である、化合物。
- 前記ジュウテリウム富化率が少なくとも90%である、請求項1に記載の化合物。
- 式(I):
[式中、R1は、H又は製薬学的に許容可能な有機又は無機カチオンであり;そしてR2、R3及びR4は、H及びDから独立に選ばれ;そして
CR2R3R4は、少なくとも70%の総ジュウテリウム富化率を有する]を有する、請求項1に記載の化合物。 - R2、R3及びR4のそれぞれが少なくとも90%のジュウテリウム富化率を有する、請求項3に記載の化合物。
- 製薬学的に許容可能なカチオンが、ナトリウム、カリウム、カルシウム、モノエタノールアミン、ジエタノールアミン、ジメチルアミノエタノール、又はモルホリンから誘導される、請求項1〜4のいずれか1項に記載の化合物。
- 医薬として使用するための請求項1〜5のいずれか1項に記載の化合物。
- 請求項1〜5のいずれか1項に記載の化合物を治療上有効量含む医薬組成物。
- 免疫機能の調節によって改善される障害の予防又は治療において使用するための請求項1〜5のいずれか1項に記載の化合物。
- 悪性過剰増殖性障害及び自己免疫疾患から選ばれる障害の治療において使用するための請求項1〜5のいずれか1項に記載の化合物。
- 悪性過剰増殖性障害が、固形腫瘍、悪性黒色腫又は血液腫瘍である、請求項9に記載の化合物。
- 自己免疫疾患が、クローン病、多発性硬化症、関節リウマチ、潰瘍性大腸炎及び全身性エリテマトーデスから選ばれる、請求項9に記載の化合物。
- ジュウテリウム富化4−ヒドロキシ−5−メトキシ−N,1−ジメチル−2−オキソ−N−[(4−トリフルオロメチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド、又はその製薬学的に許容可能な塩である化合物の製造法であって、4−ヒドロキシ−5−メトキシ−1−メチル−2−オキソ−1,2−ジヒドロ−キノリン−3−カルボン酸のC1−C4アルキルエステルと、N−メチル基が少なくとも70%のジュウテリウム富化率を有するジュウテリウム富化N−メチル−p−トリフルオロメチルアニリンとを反応させ、場合によりジュウテリウム富化4−ヒドロキシ−5−メトキシ−N,1−ジメチル−2−オキソ−N−[(4−トリフルオロメチル)フェニル]−1,2−ジヒドロ−キノリン−3−カルボキサミドと、製薬学的に許容可能な有機又は無機塩基とを反応させることによる方法。
- 式(II):
[式中、R5は、C1−C4アルキル基である]の化合物と、式(III):
[式中、
R2、R3及びR4は、H及びDから独立に選ばれ;そして
CR2R3R4は、少なくとも70%の総ジュウテリウム富化率を有する]の化合物とを、式(I):
の化合物を得るために反応させ、そして場合により、式(I)の化合物と、適切な製薬学的に許容可能な有機又は無機塩基とを反応させる、請求項12に記載の方法。 - ジュウテリウム富化率が少なくとも90%である、請求項12又は請求項13に記載の方法。
- 哺乳動物における悪性過剰増殖性障害又は自己免疫疾患の治療のための医薬組成物であって、有効量の請求項1に記載の化合物、又はその製薬学的に許容可能な塩を含む、前記組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161499848P | 2011-06-22 | 2011-06-22 | |
EP11171108A EP2537517A1 (en) | 2011-06-22 | 2011-06-22 | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
US61/499,848 | 2011-06-22 | ||
EP11171108.1 | 2011-06-22 | ||
PCT/EP2012/061798 WO2012175541A1 (en) | 2011-06-22 | 2012-06-20 | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014517051A JP2014517051A (ja) | 2014-07-17 |
JP6034861B2 true JP6034861B2 (ja) | 2016-11-30 |
Family
ID=44533811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014516322A Expired - Fee Related JP6034861B2 (ja) | 2011-06-22 | 2012-06-20 | ジュウテリウム富化4−ヒドロキシ−5−メトキシ−n,1−ジメチル−2−オキソ−n−[(4−トリフルオロ−メチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド |
Country Status (11)
Country | Link |
---|---|
US (1) | US9216956B2 (ja) |
EP (2) | EP2537517A1 (ja) |
JP (1) | JP6034861B2 (ja) |
KR (1) | KR20140035493A (ja) |
CN (1) | CN103796654B (ja) |
AU (1) | AU2012274160B2 (ja) |
BR (1) | BR112013031712B1 (ja) |
CA (1) | CA2838947A1 (ja) |
RU (1) | RU2608306C2 (ja) |
WO (1) | WO2012175541A1 (ja) |
ZA (1) | ZA201309733B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013007850A2 (pt) * | 2010-10-14 | 2016-06-07 | Immunahr Ab | 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
AU2015316824B2 (en) * | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
NZ732704A (en) * | 2014-11-19 | 2022-01-28 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
EP3067062A1 (en) * | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
CA3157394A1 (en) * | 2019-12-19 | 2021-06-24 | Helena ERIKSSON | Compounds for treatment of eye diseases associated with excessive vascularisation |
WO2021175924A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
KR20230043916A (ko) | 2020-07-23 | 2023-03-31 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질 |
MX2023008016A (es) | 2021-01-18 | 2023-07-13 | Active Biotech Ab | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. |
US20240285532A1 (en) | 2021-05-25 | 2024-08-29 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
KR20240029029A (ko) | 2021-07-02 | 2024-03-05 | 액티브 바이오테크 에이비 | 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
-
2011
- 2011-06-22 EP EP11171108A patent/EP2537517A1/en not_active Withdrawn
-
2012
- 2012-06-20 AU AU2012274160A patent/AU2012274160B2/en not_active Ceased
- 2012-06-20 JP JP2014516322A patent/JP6034861B2/ja not_active Expired - Fee Related
- 2012-06-20 WO PCT/EP2012/061798 patent/WO2012175541A1/en active Application Filing
- 2012-06-20 KR KR1020147000764A patent/KR20140035493A/ko not_active Application Discontinuation
- 2012-06-20 CN CN201280030397.8A patent/CN103796654B/zh not_active Expired - Fee Related
- 2012-06-20 US US14/125,666 patent/US9216956B2/en not_active Expired - Fee Related
- 2012-06-20 CA CA2838947A patent/CA2838947A1/en not_active Abandoned
- 2012-06-20 BR BR112013031712-4A patent/BR112013031712B1/pt not_active IP Right Cessation
- 2012-06-20 EP EP12728565.8A patent/EP2723340B1/en not_active Not-in-force
- 2012-06-20 RU RU2014101775A patent/RU2608306C2/ru active
-
2013
- 2013-12-23 ZA ZA2013/09733A patent/ZA201309733B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2723340A1 (en) | 2014-04-30 |
BR112013031712B1 (pt) | 2022-03-08 |
AU2012274160A1 (en) | 2014-01-23 |
CA2838947A1 (en) | 2012-12-27 |
EP2537517A1 (en) | 2012-12-26 |
RU2608306C2 (ru) | 2017-01-17 |
AU2012274160B2 (en) | 2016-12-15 |
JP2014517051A (ja) | 2014-07-17 |
ZA201309733B (en) | 2015-08-26 |
WO2012175541A1 (en) | 2012-12-27 |
BR112013031712A2 (pt) | 2017-07-04 |
AU2012274160A2 (en) | 2014-07-17 |
CN103796654A (zh) | 2014-05-14 |
KR20140035493A (ko) | 2014-03-21 |
RU2014101775A (ru) | 2015-07-27 |
CN103796654B (zh) | 2016-08-17 |
US9216956B2 (en) | 2015-12-22 |
US20140112946A1 (en) | 2014-04-24 |
EP2723340B1 (en) | 2017-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6034861B2 (ja) | ジュウテリウム富化4−ヒドロキシ−5−メトキシ−n,1−ジメチル−2−オキソ−n−[(4−トリフルオロ−メチル)フェニル]−1,2−ジヒドロキノリン−3−カルボキサミド | |
JP7057798B2 (ja) | mTORC1阻害剤 | |
TWI642667B (zh) | 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
KR102396307B1 (ko) | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 | |
US20230303530A1 (en) | Compounds as nuclear transport modulators and uses thereof | |
ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
CN115433187B (zh) | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 | |
WO2014019468A1 (zh) | 哌嗪并三唑类化合物及其制备方法和制药用途 | |
CN103848785A (zh) | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 | |
JP2016033166A (ja) | Arry−380の多形体、選択的erbb2(her2)阻害剤、およびそれらを含有する薬学的組成物 | |
JP2021527112A (ja) | ニューロキニン−1受容体アンタゴニストとしての化合物およびその使用 | |
CN109641887A (zh) | 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 | |
BR112020005455A2 (pt) | derivados de iminopirimidina cíclica como inibidores de cinase | |
WO2022063297A1 (zh) | 喹唑啉衍生物及其制备方法和用途 | |
WO2020156189A1 (zh) | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 | |
WO2022206705A1 (zh) | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 | |
WO2018041260A1 (zh) | 一类溴结构域识别蛋白抑制剂及其制备方法和用途 | |
JP2015534990A (ja) | 誤制御されたeIF4Eに関連する疾患又は障害を治療又は予防するための組成物及び方法 | |
WO2023143147A1 (zh) | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 | |
AU2012223281A1 (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |
WO2017180723A1 (en) | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use | |
TWI831325B (zh) | 作為atr抑制劑的萘啶衍生物及其製備方法 | |
RU2811975C9 (ru) | Конденсированное аза-гетероциклическое амидное соединение и его применение | |
RU2811975C1 (ru) | Конденсированное аза-гетероциклическое амидное соединение и его применение | |
WO2013052608A1 (en) | Optically pure apogossypolone derivatives as pan-active inhibitors of anti-apoptotic bcl-2 family proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150610 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160418 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6034861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |